New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT07312188
Summary
This study is testing a new drug called F182112, given in different combination schedules, for people with multiple myeloma that has come back or stopped responding to prior treatments. It aims to see how well the treatment works and how safe it is. The study will enroll about 90 participants who have already been treated with certain standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
Conditions
Explore the condition pages connected to this study.